Lonza

We wish you, your family and your loved ones a happy holiday season and great New Year. Thank you to all of our colleagues, partners and followers for a great 2024.

We have just announced capacity expansions at our sites in Rewari, India, and Suzhou, China. The expansions include additional hard gelatin capsule lines to support the manufacture of high-quality hard gelatin capsules, including essential and specialized capsules for the pharmaceutical and nutraceutical industries. The capacity expansion represents another step in the implementation of Lonza CHI’s hard empty capsules network strategy, focusing on long-term competitiveness and meeting the highest quality and sustainability standards. Read more: https://lnkd.in/dq4KzhPG #Capsules #Expansion #PharmaceuticalManufacturing

We have just opened our new R&D research laboratory at our site in Slough, UK. The new labs will provide an environment that is designed to foster collaboration and optimize our processes, enhancing our research capabilities. The space has been specifically designed to streamline workflows and enhance productivity, ensuring that our teams can focus on what they do best: groundbreaking research. #Biologics #Research #Biotechnology #PharmaceuticalManufacturing

Today's small molecule cancer drugs are more complex than ever, introducing new chemistry, manufacturing and control (CMC) challenges. At Lonza, we're proud to partner with our customers to overcome these challenges by developing scalable manufacturing processes and fine-tuned formulations. Our latest interactive C&EN article explores the transformative role of small molecule oncology drugs in cancer treatment and how researchers continue to identify new drug targets and more patient-friendly therapies. Furthermore, our Lonza expert Charlie Johnson shares his insights into how our industry-leading capabilities in computer-aided process design, high-throughput experimentation, solid form selection, and advanced pharmacokinetic modeling are helping our customers to drive innovation in oncology drug development. Read the full article here: https://bit.ly/3Di44br #LonzaSM #WeWorkAsOne

🔔Exciting news! The Lonza Small Molecules West Coast Business Development team will be in San Francisco Bay Area for J.P. Morgan Health Conference from January 13th to 16th, 2025. We look forward to discussing the latest innovations and future trends shaping the small molecules market, and can’t wait to engage with industry experts and thought leaders. 💻 Connect with us Tanner Call, Duke Chalker, Elizabeth Crofts to schedule a meeting.  💬 Let’s talk chemistry, drug development and manufacturing, and all things biotech/pharma. #AHealthierWorld #SmallMolecules #PharmaceuticalManufacturing #WeWorkAsOne

Biologics in Focus – December edition is ready for you to read. As we approach the New Year, we’re excited to share the latest updates shaping the future of biologics and wish you a holiday season filled with joy and relaxation. Some of this month’s highlights include: - A review of emerging biotechs and how they can accelerate early-stage development through partnerships - Updates on advancements in gene expression control with our enhanced GS® CHO Vector Technology - Expert insights into successful biologics tech transfers - A case study on Synaffix’s platform integration into BigHat’s AI-driven protein engineering to accelerate ADC development - The expansion of bioconjugation capabilities in Visp, Switzerland, with two new manufacturing suites to produce complex biotherapeutics like antibody-drug conjugates (ADCs). Join us in driving innovation and shaping the future of biologics in the coming year—one breakthrough at a time. #LonzaBio #Pharma #Biotechnology #ThePeoplePoweringBiologics #BiologicsInFocus

This morning, we announced our new “One Lonza” strategy to focus on our CDMO business, reshape our operating model, elevate execution in manufacturing and engineering, and expand through an impartial approach to buy and build. As we focus on our core CDMO business, we plan to exit the Capsules & Health Ingredients (CHI) business at an appropriate time and in the best interest of shareholders and stakeholders. Our CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities. This simplified structure is designed to enhance customer experience, provide scalability for future growth and strengthen our multimodality offering. Learn more here: https://lnkd.in/dAZg2Z_3 #CDMO #StrategyUpdate #Lonza

Advances in polymer science have ushered in a new era of capsules capable of targeted drug delivery. This targeted approach is crucial for treatments that require local delivery, for example for Crohn's disease, exocrine pancreatic insufficiency, or Clostridium difficile infection. The creation of a bilayer capsule—comprised of a structural layer for shape and a functional layer for targeted release—both required the development of new technologies and could itself serve as an enabling technology for future therapies. Watch the full video here: https://lnkd.in/gi7jhMAz #PharmaceuticalManufactuirng #Capsules #DrugDelivery #Innovation #Research

At this year’s 10th Winter Process Chemistry Conference on December 10th, our #SmallMolecules expert, Dr. Bernhard Gutmann, will be presenting a talk entitled ''Continuous Flow Techniques for Pharmaceutical Manufacturing''. At Lonza, we leverage continuous flow and microreactor technology to reduce production costs, increase product yield and consistency, and strengthen process robustness. Join Bernhard's talk to learn more about: * The advantages and challenges of continuous flow processes * Industry examples of using continuous processing for API manufacturing * Lonza's mini-monoplant technology #LonzaSM #WeWorkAsOne #flowchemistry

"We process chemists can no longer simply refine the med-chem route to create commercially viable synthetic routes. As we've talked with customers, it's clear there's a significant need for flexible manufacturing solutions to overcome challenges like regulatory hurdles and the development of these very complex APIs we see today," said Simon Wagschal in an interview with Outsourced Pharma. Simon Wagschal and Aaron Johnson, who work in Small Molecules R&D at Lonza, recently spoke about route scouting and AI applications in pharma development and manufacturing. By combining retrosynthetic AI tools with Lonza's supply chain database, it is possible to assess the viability of a molecule for scaling up. Read the interviews here: ▶️ https://lnkd.in/d-U4rtSf ▶️ https://lnkd.in/dfDqqSGU #AHealthierWorld #SmallMolecules #PharmaceuticalManufacturing #Innovation #AI